Pacira BioSciences $171.8M Q1 Revenue Forecast; PharmaCorp RX to Acquire 8 Pharmacies
PCRX•Pacira BioSciences is expected to report Q1 EPS of $0.55 on $171.8 million revenue, with a trailing P/E of 157.63, debt-to-equity 0.66 and current ratio 4.54 indicating strong liquidity. PharmaCorp RX will acquire eight PharmaChoice Canada–branded pharmacies in Eastern Canada to expand its community pharmacy network.
1. Pacira BioSciences Earnings Forecast
Pacira BioSciences expects to report first-quarter EPS of $0.55 on revenue of $171.8 million when it releases results on April 30, 2026. Its trailing twelve-month P/E ratio stands at 157.63, alongside a debt-to-equity ratio of 0.66 and a current ratio of 4.54, underscoring solid liquidity and investor growth expectations.
2. PharmaCorp RX Pharmacy Acquisitions
PharmaCorp RX entered into definitive share purchase agreements on April 28 to acquire 100% stakes in eight PharmaChoice Canada–branded community pharmacies across Eastern Canada, significantly expanding its geographic footprint and operating scale within the pharmacist-led ownership platform.
